Madrid, 23 de mayo de 2017
This year marks the 20th anniversary of the incorporation of generic medicines (EFG) into Spanish healthcare. It is a good moment to analyze the evolution of these two decades and to take stock of its contribution to the National Health System and to our gross domestic product (GDP). But also to reflect on the need to launch new initiatives to exploit. Its great potential to improve access to medicines, the sustainability of our health system and the economic development of the country.Read More
Blog aimed at anyone who wants to express opinions through comments, suggestions and articles of collaborations.
We offer everyone, this place to spread more rigorous knowledge of the generic medicines in the Spanish society.
We create enhanced access to medicines, reducing inequalities, directly leading to improved patient outcomes. We compete, stimulating the medicines industry to innovate. We innovate, enriching patient benefit.
We provide a stable and resilient supply of high-quality medicines, manufactured and developed according to stringent EU regulatory requirements, for Europe’s patients and healthcare providers.
Our high-quality cost-effective medicines account for well over 54% of all prescription medicines used to treat European patients. We are the heart of public health delivery in Europe. We generate cost savings of more than €35bn each year ensuring the viability of Europe’s healthcare systems and enable them to invest in new medicines and other treatments that Europe’s patients increasingly need.
Use of our medicines supports the economic sustainability of Europe’s healthcare systems. We contribute to Europe’s economies, researching, developing and manufacturing in most European countries the majority of medicines used in the EU, sustaining more than 150.000 high skilled, high value direct jobs. As a leading knowledge based industry we will continue to work with Europe’s policy makers, legislators and regulators to create the right environment to support and strengthen the economic sustainability of our industry so that we can continue to contribute to European patients and society.
We build constructive partnerships, focused on a strong and stable collaboration with patients and patient organisations, the EU institutions, governments and regulators, healthcare professionals and others to further enhance public health in Europe.